Freestone Grove Partners LP Invests $224,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)

Freestone Grove Partners LP acquired a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 7,433 shares of the biopharmaceutical company's stock, valued at approximately $224,000.

Several other institutional investors have also recently modified their holdings of the company. Arizona State Retirement System boosted its holdings in TG Therapeutics by 0.9% during the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock valued at $1,283,000 after acquiring an additional 364 shares during the period. Blue Trust Inc. boosted its holdings in TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 371 shares during the period. Summit Investment Advisors Inc. boosted its holdings in TG Therapeutics by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock valued at $440,000 after acquiring an additional 463 shares during the period. Brookstone Capital Management boosted its holdings in TG Therapeutics by 3.7% during the 4th quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company's stock valued at $527,000 after acquiring an additional 624 shares during the period. Finally, Daymark Wealth Partners LLC boosted its holdings in TG Therapeutics by 1.7% during the 4th quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company's stock valued at $1,249,000 after acquiring an additional 689 shares during the period. 58.58% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and set a $55.00 target price on shares of TG Therapeutics in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, TG Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $40.80.

TG Therapeutics Trading Down 0.6%

TGTX traded down $0.22 during midday trading on Friday, reaching $33.64. 2,237,034 shares of the company's stock traded hands, compared to its average volume of 3,022,129. The firm has a fifty day moving average of $38.90 and a two-hundred day moving average of $33.70. The stock has a market capitalization of $5.34 billion, a price-to-earnings ratio of -336.37 and a beta of 2.21. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. TG Therapeutics, Inc. has a 52 week low of $15.16 and a 52 week high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). The business had revenue of $120.86 million for the quarter, compared to the consensus estimate of $117.07 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company's revenue for the quarter was up 90.4% on a year-over-year basis. During the same period in the previous year, the company earned ($0.07) EPS. On average, equities analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.